GlaxoSmithKline and Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate, reviving their efforts against the pandemic after a setback in. | February 27, 2021
European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis
NR2E3), for the treatment of both retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA).
The prevalence of RP in Europe is estimated at approximately 165,000 patients and the prevalence of LCA in Europe is estimated at approximately 40,000 patients. Globally, the number of people suffering from RP and LCA is estimated to be around 2.0 million and 0.2 million, respectively. We believe the granting of this designation by the European Commission validates the potential of our modifier gene therapy platform to treat many inherited retinal diseases, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen.
Date Time
New report looks at uptake of telehealth in antenatal care during COVID-19 lockdowns
Almost 1 in 10 antenatal services for March to September 2020 were delivered via telehealth according to a new report by the Australian Institute of Health and Welfare (AIHW).
The report, Antenatal care during COVID-19, 2020, includes information on antenatal care services, both face-to-face and telehealth, claimed through the Medicare Benefits Schedule (MBS). The report covers a range of private antenatal services and it does not include information on antenatal care provided by public hospitals.
‘These antenatal specific telehealth services were introduced in March 2020, to enable Australians to stay at home where possible to reduce the risk of COVID-19 transmission,’ said AIHW spokesperson Ms. Bernice Cropper.
(1)
PALM HARBOR, FL / ACCESSWIRE / February 23, 2021 / Regener-Eyes
®, a leading first-in-class biologic eye drop made of naturally-occurring cytokines and growth factors, today announced the addition of Dr. Art Epstein to its Clinical Advisory Board. We are excited to have Dr. Art Epstein join our clinical advisory board. He is a highly respected eye care professional, and will bring valuable insight to our company s efforts, commented C. Randall Harrell, M.D., CEO and Founder of Regener-Eyes
®. We are honored to add Dr. Epstein to our existing board alongside our other impressive members, Dr. Marguerite McDonald, Dr. Eric Donnenfeld, Dr. Paul Karpecki, Dr. Walt Whitley, Dr. Scott Schacter and Dr. Ahmed Fahmy.